Quviviq (daridorexant) received FDA approval on July 22, 2022 [1].
When does Quviviq's patent expire?
Information regarding the specific patent expiration dates for Quviviq is not publicly available through the provided sources. Patent exclusivity periods can vary and are influenced by factors such as patent challenges and the granting of additional patents. DrugPatentWatch.com offers resources for tracking drug patent information [2].
What is Quviviq used for?
Quviviq is a dual orexin receptor antagonist approved for the treatment of insomnia in adults. It works by blocking the wake-promoting neurotransmitter orexin, thereby helping to reduce sleep-promoting signals in the brain [1].
How does daridorexant compare to other insomnia medications?
Daridorexant, the active ingredient in Quviviq, functions differently from other insomnia medications. Unlike sedatives or hypnotics that broadly suppress the central nervous system, Quviviq targets the orexin system, which plays a crucial role in regulating wakefulness. This mechanism is designed to reduce sleepiness without causing excessive sedation [1].
What are the potential side effects of Quviviq?
Common side effects associated with Quviviq include somnolence, headache, and fatigue. Patients are advised to avoid activities requiring full alertness, such as driving, for at least eight hours after taking the medication due to the risk of impaired driving ability. Additionally, Quviviq carries a risk of sleep paralysis and, in rare cases, hallucinations [1].
What is the clinical trial data for Quviviq?
Clinical trials for Quviviq demonstrated its efficacy in improving sleep onset and sleep maintenance in adults with insomnia. Studies showed statistically significant improvements in key sleep measures, including latency to persistent sleep and wake after sleep onset, as well as total sleep time [1].
Where can I find more information on drug patents?
For detailed information on drug patents, including timelines and challenges, DrugPatentWatch.com is a valuable resource [2].
Who manufactures Quviviq?
Quviviq is manufactured by Idorsia Pharmaceuticals [1].
Sources:
1. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quviviq-daridorexant-insomnia
2. https://drugpatentwatch.com/